Usage of Benzodiazepines or Opiates Among Members Who are in Consistent Methadone Treatment in...

Usage of Benzodiazepines or Opiates Among Members Who are in Consistent Methadone Treatment in Philadelphia

Community Behavioral Health (CBH) Replication of Community Care Behavioral Health (CCBH) Study

Matthew O. Hurford, M.D.Chief Medical Officer, CBHAssistant Professor, Univ. of Penn.

ObjectiveIdentify Community Behavioral

Health (CBH) Members in Philadelphia who are in methadone treatment and concurrently on benzodiazepines or opiates.

Data sourcesAnaylsis period: July 1, 2010 –

September 30, 2010Paid methadone clinic claims

from all contracts for the analysis period.

Paid Medicaid pharmacy claims for the analysis period.

Methodology Identify members in methadone treatment for at least

ten days in Q3 2010. Identify members in the above population who also filled

prescriptions for benzodiazepines or opiates during the same period.

Generate a distribution based on methadone providers in all the contracts.

Generate age group, gender, and racial distributions for the above population.

Identify the benzodiazepines and opiates used. Identify physicians and specialties to the extent possible.

Although this analysis was included in the original study by CCBH, CBH’s data warehouse contains very little information of this kind. Therefore, we were unable to produce a meaningful replication of this analysis.

ResultsTable 1 shows the distribution of

members in methadone treatment and those with concurrent benzodiazepine or opiate prescriptions during the analysis period, by Philadelphia zip code.

Table 1

Table 1, continued

ResultsTables 2, 3, and 4 show

demographics for members with concurrent methadone and benzodiazepine/opiate usage.

Table 2: Age Distribution

Table 2:

Table 3: Gender Distribution

Table 4: Racial Distribution

ResultsTable 5 shows the methadone

provider distribution.

Table 5

ResultsTable 6 shows the distribution of

members based on whether a benzodiazepine or opiate was prescribed. (Benzo = 1 if the member had a prescription for a benzodiazepine; otherwise Benzo = 0. Opiate = 1 if the member had a prescription for an opiate; otherwise Opiate = 0.)

Table 6

ResultsTables 7 and 8 show the details

of the benzodiazepines or opiates prescribed. Members had 2497 benzodiazepine prescriptions and 3067 opiate prescriptions.

Table 7: Benzodiazepines

Table 8: Opiates

Comparison with CCBH DataCCBH shows that 45.8% of MAT

patients have concurrent prescriptions for benzodiazepines or opiates.

CBH shows that 45.6% of MAT patients have concurrent benzodiazepine or opiate prescriptions.

Comparison with CCBH DataCCBH shows 44.9% of MAT patients with

concurrent prescriptions for benzodiazepines or opiates are ages 18-34; for CBH that number is 31.7%.

CCBH shows 31.3% of patients with concurrent scripts are ages 35-50 having concurrent scripts; for CBH that number is 42.2%.

CCBH shows 23.5% of MAT with concurrent scripts are 51-64; for CBH that number is 25.5%.

CCBH shows 0.3% of MAT patients having concurrent scripts are 65 or older; for CBH that number is 0.5%.

Comparison with CCBH DataCCBH shows 57.6% of MAT

patients having concurrent scripts are female, whereas CBH shows 58.9% of patients who have concurrent scripts are female.

Percentages for male patients are 42.4% and 41.1%, respectively.

Comparison with CCBH DataCCBH found that 7% of patients having

concurrent scripts were African-American. 87.3% were Caucasian, and 5.8% fell into other racial categories.

CBH found that 22.5% of patients with concurrent scripts were African-American or Black, 60.7% were Caucasian, and 16.8% fell into other racial categories.

Note that racial categories are constructed differently in the two BH/MCOs.

Comparison with CCBH DataCCBH providers contributed 0.1%

to 33.1% to the sample.CBH providers contributed a

range of 2.87% to 22.5%.

Comparison with CCBH Data

27.7% of CCBH’s patients with concurrent scripts had a prescription for an opiate.

50.2% had a prescription for a benzo.22% had a prescription for both. In CBH, 27.8% of patients with

concurrent scripts had a prescription for an opiate.

41.9% had a prescription for a benzo.30.3% had a prescription for both.

Comparison to CCBH DataOf 3313 concurrent benzo scripts

in CCBH, clonazepam was prescribed the most often, at 17.3%

The same was true for CBH, where clonazepam made up 38.4% of concurrent benzo scripts.

Comparison to CCBH DataCCBH CBH

Alprazolam 12.4% 33.7%Lorazepam 2.7% 7.4%Temazepam 2% 9.9%Diazepam 1.6% 7.2%Triazolam 0.2% 0.7%Flurazepam <0.1% 0.4%Chlordiazepoxide <.01% 0.3%Oxazepam <0.1% -----Estazolam ----- 0.3%Clorazepate ----- <0.1%

Comparison to CCBH DataOf 1737 concurrent opiate scripts

in CCBH, 19% were for hydrocodone.

21.5% of CBH’s concurrent opiate scripts were for hydrocodone; CBH members were more likely to have scripts for oxycodone (30.2%).

Comparison to CCBH DataCCBH CBH

Oxycodone 17.6% 30.2%Tramadol 4.7% 13.8%Codeine 3% 14.4%Buprenorphine 2.4% 5.7%Methadone 1.3% 5.5%Propoxyphene 0.8% 4.1%Hydromorpohone 0.6% -----Fentanyl 0.5% 1.2%Morphine ----- 2.2%Diphenoxylate ----- 0.9%Meperidine ----- 0.2%Naltrexone ----- <0.1%Oxymorphone ----- <0.1%